ACP-103
ACP-103-008
Phase 2 small_molecule completed
Quick answer
ACP-103 for Schizophrenia is a Phase 2 program (small_molecule) at ACADIA PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ACADIA PHARMACEUTICALS INC
- Indication
- Schizophrenia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed